A single dose of engineered CAR-T immune cells enabled kidney transplants for three highly sensitized patients—two men and one woman—who are typically ineligible due to high antibody levels.

The report suggests that traditional treatments like dialysis are exhausting and time-consuming, highlighting the potential quality‑of‑life benefits if CAR-T–assisted transplantation becomes more common.

The findings are published in the New England Journal of Medicine across two independent studies, providing validation from separate teams.

The recipients have lived with new kidneys for over a year without notable side effects, indicating the approach may be safe and durable in this context.

Experts, including Allan Kirk and Ali Naji, say this could be a major breakthrough and a game changer for expanding access to kidney transplants for highly sensitized patients.

The case of one woman with multiple autoimmune diseases underscores the severe risks of organ failure and repeated transplants, including dialysis burden and health decline prior to CAR-T therapy.

Highly sensitized patients have antibodies that attack donor organs, leaving roughly 91,000 people on U.S. kidney transplant waiting lists with only 5–10% eligibility due to rejection risk.

CAR-T therapy involves engineering a patient’s T cells to target cells that produce problematic antibodies, thereby dampening the immune response that blocks transplantation.